Impact Factor 3.831
2017 JCR, Clarivate Analytics 2018

Frontiers journals are at the top of citation and impact metrics

Review ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Pharmacol. | doi: 10.3389/fphar.2019.00606


 V'yacheslav LEHEN'KYI1, 2*, Aline Hantute-Ghesquier1, 2, Aurélien Haustrate1, 2 and Natalia Prevarskaya1, 2
  • 1Université de Lille, France
  • 2INSERM U1003 Laboratoire de Physiologie Cellulaire, France

Monoclonal antibodies (mAbs) represent a rapidly growing pharmaceutical class of protein drugs which becomes an important part of the precision therapy. mAbs are characterized by their high specificity and affinity for the target antigen which is mostly present on the cell surface. Ion channels are a large family of trans-membrane proteins that control ion transport across the cell membrane. They are involved in almost all biological processes in both health and disease and are widely considered as prospective targets. However, no antibody-based drug targeting ion channel has been developed so far that has progressed to clinical use. Thus, we provide a comprehensive review of the elaborated mAbs against ion channels, describe their mechanisms of action and discuss their therapeutic potential.

Keywords: Monoclonal antibody, ion channel, therapy, Mechanism, targeting

Received: 08 Nov 2018; Accepted: 14 May 2019.

Edited by:

Jean-François Desaphy, University of Bari Aldo Moro, Italy

Reviewed by:

Theodore R. Cummins, School of Medicine, Indiana University Bloomington, United States
Ciro Leonardo Pierri, University of Bari Aldo Moro, Italy  

Copyright: © 2019 LEHEN'KYI, Hantute-Ghesquier, Haustrate and Prevarskaya. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Dr. V'yacheslav LEHEN'KYI, Université de Lille, Lille, France,